Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Intensive Care Platform Trial (INCEPT)
NCT06667999Phase 4Recruiting
- Sponsor
- Anders Perner
- Start
- Jun 2025
- Primary completion
- Dec 2035
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 4, randomised, open-label trial of albumin (human) and low molecular weight heparin calcium in critical illness (5 arms), sponsored by Anders Perner. Primary endpoints: INCEPT core outcomes, Days alive without life support at day 30 and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
albumin (human)low molecular weight heparin calcium
03
Conditions
critical illness
Beyond the preview
Go deeper on NCT06667999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667999.